Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation-Reference-Cited by-同舟云学术

Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation

Published:2018-09-10 Issue:18 Volume:61 Page:8282-8298
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Laghezza Antonio¹,Piemontese Luca¹^ORCID,Cerchia Carmen²,Montanari Roberta³,Capelli Davide³,Giudici Marco⁴,Crestani Maurizio⁴,Tortorella Paolo¹,Peiretti Franck⁵,Pochetti Giorgio³,Lavecchia Antonio²^ORCID,Loiodice Fulvio¹^ORCID

Affiliation:

1. Dipartimento Farmacia-Scienze del Farmaco, Università degli Studi di Bari “Aldo Moro”, Via Orabona 4, 70125 Bari, Italy

2. Dipartimento di Farmacia, “Drug Discovery” Laboratory, Università degli Studi di Napoli “Federico II”, Via D. Montesano 49, 80131 Napoli, Italy

3. Istituto di Cristallografia, Consiglio Nazionale delle Ricerche, Montelibretti, 00015 Monterotondo Stazione, Roma, Italy

4. Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy

5. Aix Marseille Université, INSERM 1263, INRA 1260, C2VN, 13005 Marseille, France

Funder

Universita degli Studi di Bari Aldo Moro

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00835

Reference63 articles.

1. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

2. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

3. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

4. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

5. Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis;European Journal of Medicinal Chemistry;2024-10

2. A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties;European Journal of Medicinal Chemistry;2024-09

3. Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ;2024-07-18

4. Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ;2024-07-18

5. Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease;Journal of Cellular and Molecular Medicine;2024-06